UOC
DAWN

UBS O'Connor’s Day One Biopharmaceuticals DAWN Stock Holding History

UBS O'Connor’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-107,249
Closed -$697K – 330
2025
Q2 		$697K Sell
107,249
-6,001
-5% -$41.3K 0.02% 253
2025
Q1 		$898K Buy
113,250
+63,230
+126% +$681K 0.02% 194
2024
Q4 		$634K Buy
+50,020
New +$696K 0.02% 263
2023
Q2 		– Sell
-28,053
Closed -$375K – 598
2023
Q1 		$375K Sell
28,053
-15,883
-36% -$310K 0.01% 484
2022
Q4 		$946K Buy
43,936
+6,936
+19% +$142K 0.02% 567
2022
Q3 		$741K Buy
+37,000
New +$787K 0.01% 775

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

UBS O'Connor's DAWN Position: Q3 2025 in Review

UBS O'Connor sold out of Day One Biopharmaceuticals (DAWN) in Q3 2025, closing a stake of 107,249 shares — an estimated $697K sold.

UBS O'Connor first reported a position in DAWN in Q3 2022 and held it in 6 quarters. The position peaked at $946K in Q4 2022. 172 funds tracked by Wall St. Rank hold DAWN as of Q3 2025.

  • UBS O'Connor reported no remaining Day One Biopharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 107,249 Day One Biopharmaceuticals shares in Q3 2025, an estimated $697K.
  • UBS O'Connor first reported a position in Day One Biopharmaceuticals in Q3 2022 and held it in 6 quarters.
  • UBS O'Connor's Day One Biopharmaceuticals position peaked at $946K in Q4 2022.
  • 172 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.